Question 8744 — maternity health insurance

Summary

Ms. Lisette Pollet draws the attention of the Minister of Labor, Health, Solidarity and Families to the worrying consequences that would result from a unilateral decision of the Economic Committee for Health Products (CEPS), expected on July 23, 2025, aimed at imposing a significant reduction in reimbursement rates for numerous orthopedic medical devices. Since 2013, manufacturers in the sector have suffered declines repeated and substantial tariffs: up to -29% for certain maxillofacial surgery devices, -17% on hip implants, -15% on orthopedic cement or even -11% for knee prostheses. This pressure is exerted at a time when health needs are increasing, particularly due to the aging of the population and economic constraints are intensifying: a 4 to 6-fold increase in health costs. certification linked to European regulations, 17% increase in raw material prices, explosion in production costs. For the year 2025, CEPS has been set a savings objective of 200 million euros on all medical devices registered on the list of reimbursable products and services (LPPR). In this context, it intends to impose a price reduction of 33 million euros on the orthopedic sector alone - i.e. more than 16% of the overall effort, while this sector only represents around 8% of LPPR expenditure. This obvious imbalance arouses great concern among the stakeholders concerned. Aware of the issues of budgetary sustainability, the orthopedics manufacturers, grouped within their union, presented a responsible and well-argued counter-proposal in June: 27 million euros in savings generated over 3 years, of which 15.4 million from 2025. They also proposed opening negotiations on alternative levers, such as the proper use of products, the optimization of care pathways, the reduction of hospitalization times or the development of outpatient surgery. Despite this, these constructive proposals were rejected by the CEPS, which maintains a strictly pricing approach, without taking into account the repercussions on the sector and on the supply of care. However, companies in the sector continue, despite degraded profitability, to assume essential missions at their own expense: implant logistics, management of surgical deposits, training of health professionals. This model is no longer sustainable. Due to lack of prospects, some companies are withdrawing devices from the market, in particular those intended for rare indications (such as elbow prostheses or implants). spine), to the detriment of patients. France, long recognized for its excellence in orthopedics, is seeing its industrial fabric weakened: since 2016, eight French companies in the sector have moved under foreign flags and four have ceased their activities. This loss of industrial sovereignty and attractiveness is all the more paradoxical as the Government displays strong ambitions in terms of reindustrialization, health sovereignty and innovation. Orthopedics is a field with high added value, both for patients and for the health system: innovations enable better quality care, facilitate the work of surgeons, encourage the use of outpatient care and help to relieve congestion in hospitals. An exclusively budgetary pricing policy compromises this progress and contradicts the strategic objectives displayed by the state. She therefore asks how she intends to reconcile this unilateral reduction measure with her commitments to reindustrialization, health sovereignty and medical innovation. She asks him if a review of the effort requested from the orthopedic sector is envisaged, as part of a constructive dialogue with the manufacturers concerned.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.